Cargando…

P1557: A STUDY ON THE IMMUNOGENICITY OF COVID-19 VACCINE IN PATIENTS WITH HEMATOLOGIC MALIGNANCY

Detalles Bibliográficos
Autores principales:	Mesina, Flordeluna, Eryll Sy, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430034/ http://dx.doi.org/10.1097/01.HS9.0000973104.49710.4c

Ejemplares similares

P1546: HEMATOLOGIC ADVERSE EVENTS AFTER COVID-19 VACCINATION IN THE PHILIPPINES: A NATIONAL DATABASE STUDY
por: Mesina, Flordeluna, et al.
Publicado: (2023)

Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study
por: Mesina, Flordeluna Z., et al.
Publicado: (2023)

Severe Relapsed Autoimmune Hemolytic Anemia after Booster with mRNA-1273 COVID-19 vaccine
por: Mesina, Flordeluna Z.
Publicado: (2022)

1557. First Report of Nocardia veterana Soft Tissue Abscess
por: Radcliffe, Christopher, et al.
Publicado: (2020)

PB2247: BURDEN OF SYMPTOMS AND SYMPTOM EXPERIENCE OF FILIPINO MYELOPROLIFERATIVE NEOPLASM PATIENTS: A QUALITATIVE PHENOMENOLOGICAL STUDY
por: Mesina, Flordeluna, et al.
Publicado: (2023)

P1712: CORONAVIRUS ANXIETY LEVEL AND COVID 19 VACCINE ATTITUDE AMONG HEMATOLOGICAL MALIGNANCY PATIENTS
por: Güven, Z., et al.
Publicado: (2022)

P1574: ANTINEOPLASTIC THERAPY FOR HEMATOLOGIC MALIGNANCIES DURING COVID-19
por: Chudnova, T., et al.
Publicado: (2022)

P1557: DISTINGUISHING OF IRON REFRACTORY IRON DEFICIENCY ANEMIA FROM IRON DEFICIENCY ANEMIA AND THALASSEMIA TRAIT BY SYSMEX RESEARCH RED CELL PARAMETERS
por: Yilmaz, E., et al.
Publicado: (2022)

1557. Acyclovir-Resistant (ACV-R) Herpes Simplex Virus (HSV) Disease in Patients with Hematologic Malignancies (HM) and Hematopoietic-Cell Transplant (HCT) Recipients
por: Pandit, Alisha, et al.
Publicado: (2018)

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies
por: Martinez Lopez, Joaquin, et al.
Publicado: (2022)

Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
por: Ikeda, Daisuke, et al.
Publicado: (2022)

586. Immunogenicity of COVID-19 mRNA Vaccines in Patients with Lymphoid Malignancies
por: Izaguirre, Natalie E, et al.
Publicado: (2021)

Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
por: Teh, Joanne S. K., et al.
Publicado: (2022)

P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Tamariz-Amador, L.-E., et al.
Publicado: (2022)

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
por: Chien, Kelly S., et al.
Publicado: (2022)

0.26-Hz-linewidth ultrastable lasers at 1557 nm
por: Wu, Lifei, et al.
Publicado: (2016)

Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review
por: Piechotta, Vanessa, et al.
Publicado: (2022)

P1745: ADHERENCE TO TREATMENT OF HEMATOLOGICAL MALIGNANCIES PATIENTS WITH ANXIETY AND DEPRESSION
por: Vybornykh, D. E., et al.
Publicado: (2022)

1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study
por: Shepherd, S.T.C., et al.
Publicado: (2021)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

P1568: EARLY, BUT NOT LATE USE OF REMDESVIR AND CONVALESCENT PLASMA REDUCES MORTALITY OF COVID 19 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES – A STUDY OF KROHEM
por: Aurer, I., et al.
Publicado: (2022)

P1555: COVID‑19 INFECTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A SINGLE-CENTRE SURVEY DURING THE LATEST OMICRON WAVE IN CHINA
por: Zhu, Xiaolu, et al.
Publicado: (2023)

COVID-19 Infection in Children with Down Syndrome and Hematologic Malignancies
por: Foxworthy, Blake, et al.
Publicado: (2022)

P1700: EARLY APPEARANCE OF CARDIOTOXICITY, IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES (HM)
por: Antoniadi, K., et al.
Publicado: (2022)

Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
por: Thookhamme, Chayapa, et al.
Publicado: (2023)

Immunogenicity profile after COVID-19 vaccination in patients with onco-hematological diseases
por: de Almeida, João Bosco, et al.
Publicado: (2023)

Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
por: Pasikhova, Yanina, et al.
Publicado: (2022)

P1543: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES THAT NEED VASOACTIVE SUPPORT – SINGLE CENTER STUDY
por: Vitkon, Roy, et al.
Publicado: (2023)

P1592: MATCHED CONTROL COMPARISON OF SURVIVAL OF HOSPITALIZED COVID-19 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES, DATA FROM A LARGE TERTIARY CENTER REGISTRY
por: Lucijanic, M., et al.
Publicado: (2022)

Immunogenic Cell Death in Hematological Malignancy Therapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections
por: Prakash, Rishab, et al.
Publicado: (2022)

P1723: A FEASIBILITY STUDY OF PEER SUPPORT IN FAMILY CAREGIVERS OF PATIENTS NEWLY DIAGNOSED WITH HEMATOLOGIC MALIGNANCY
por: Nielsen, I. H., et al.
Publicado: (2022)

P1588: A SINGLE CENTER COMPARATIVE CLINICAL ANALYSIS OF THE SARS-COV-2 INFECTION BEFORE AND AFTER VACCINATION IN PATIENTS DIAGNOSED WITH HEMATOLOGIC MALIGNANCIES
por: Jiménez, M., et al.
Publicado: (2022)

Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
por: Agha, Mounzer, et al.
Publicado: (2021)

P1552: AN IMMUNE ATLAS OF THE DYSFUNCTIONAL CELLULAR AND ANTIBODY RESPONSE TO COVID-19 VACCINATION IN HEMATOLOGICAL PATIENTS WITH A MATURE B-CELL NEOPLASM
por: Martín-Sánchez, Esperanza, et al.
Publicado: (2023)

532. COVID-19 Pneumonia in Patients with Hematologic Malignancies – A Report from the US Epicenter
por: Plate, Markus, et al.
Publicado: (2020)

P1513: REDUCTION OF THE PROPHYLACTIC EFFECT OF TIXAGEVIMAB-CILGAVIMAB IN THE OMICRON ERA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND WITHOUT ANTIBODY RESPONSE FOLLOWING SARS-COV-2 VACCINATION.
por: Callegari, Chiara, et al.
Publicado: (2023)

P1590: OUTCOME OF HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES –A TERTIARY CANCER CENTER EXPERIENCE
por: Kim, K., et al.
Publicado: (2022)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fmp8tk3k14l2lgjtd99o0tgof3